16-30 of 235
What to Know About the No Surprises Act
Perspectives with the AMAWhat to Know About the No Surprises Act
Navigating Treatment Choices for Crohn’s Disease & Ulcerative Colitis
GI InsightsNavigating Treatment Choices for Crohn’s Disease & Ulcerative Colitis
Reviewing the Role of Tofacitinib in Ulcerative Colitis
GI InsightsReviewing the Role of Tofacitinib in Ulcerative Colitis
The Pharmacological Perspective: Treatment Options & the 2020 IBS Guidelines
GI InsightsThe Pharmacological Perspective: Treatment Options & the 2020 IBS Guidelines
- advertisement
Lawsuit Against HHS Highlights 340B Drug Pricing Dispute
The Drug ReportLawsuit Against HHS Highlights 340B Drug Pricing Dispute
FDA Issues EUA for Pfizer-BioNTech COVID-19 Vaccine
The Drug ReportFDA Issues EUA for Pfizer-BioNTech COVID-19 Vaccine
Exploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
The Drug ReportExploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
How Neuromodulators Can Treat Functional GI Disorders
GI InsightsHow Neuromodulators Can Treat Functional GI Disorders
Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease
AudioAbstractsProactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease
Research Efforts in the Race to Find a Cure for COVID-19
COVID-19: On The FrontlinesResearch Efforts in the Race to Find a Cure for COVID-19
- advertisement
Investigating the Circulation of Counterfeit COVID-19 Medications
COVID-19: On The FrontlinesInvestigating the Circulation of Counterfeit COVID-19 Medications
2020 Crohn’s & Colitis Congress: How & When to Perform Disease & Drug Monitoring
Crohn’s & Colitis Foundation Perspectives2020 Crohn’s & Colitis Congress: How & When to Perform Disease & Drug Monitoring
The DEA’s Adjustment to Schedule II Rules Amid COVID-19
The Drug ReportThe DEA’s Adjustment to Schedule II Rules Amid COVID-19
